drugset / Trial / NCT03410446
Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care. The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.
Timeline
- Start
- 2018-07-16
- Primary completion
- 2021-11-27
- Completion
- 2021-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 50 mg | Intranasal |
| Subject | Ketamine | Small molecule | 100 mg | Intranasal |
| Subject | Ketamine | Small molecule | 150 mg | Intranasal |